NeuBase to Present at the Jefferies London Healthcare Conference
November 03, 2021 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference
September 28, 2021 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using...
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer
September 14, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference
September 01, 2021 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the...
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
August 12, 2021 16:01 ET
|
NeuBase Therapeutics, Inc.
Further demonstrated broad potential of novel genetic medicine platform with in vivo data in three diseases driven by different genetic mechanisms of diseasePresented preclinical data showing...
NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth
June 08, 2021 12:30 ET
|
NeuBase Therapeutics, Inc.
Data presented today at NeuBase’s R&D Day show functional rescue of myotonic dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions program to enter the clinic in CY...
NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th
June 02, 2021 09:00 ET
|
NeuBase Therapeutics, Inc.
Company to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington’s disease program and unveil a new...
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
May 25, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
May 20, 2021 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of...